ATE517897T1 - Heterobicyclische inhibitoren von hvc - Google Patents

Heterobicyclische inhibitoren von hvc

Info

Publication number
ATE517897T1
ATE517897T1 AT06708816T AT06708816T ATE517897T1 AT E517897 T1 ATE517897 T1 AT E517897T1 AT 06708816 T AT06708816 T AT 06708816T AT 06708816 T AT06708816 T AT 06708816T AT E517897 T1 ATE517897 T1 AT E517897T1
Authority
AT
Austria
Prior art keywords
hvc
heterobicyclic
inhibitors
heterobicyclic inhibitors
substituted
Prior art date
Application number
AT06708816T
Other languages
English (en)
Inventor
Kenneth Alan Simmen
Sarvajit Chakravarty
Barry Hart
Dominique Louis Nestor Surleraux
Tse-I Lin
Oliver Lenz
Pierre Raboisson
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE517897T1 publication Critical patent/ATE517897T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06708816T 2005-03-25 2006-03-27 Heterobicyclische inhibitoren von hvc ATE517897T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66515105P 2005-03-25 2005-03-25
US68040505P 2005-05-12 2005-05-12
PCT/EP2006/061070 WO2006100310A1 (en) 2005-03-25 2006-03-27 Heterobicylic inhibitors of hcv

Publications (1)

Publication Number Publication Date
ATE517897T1 true ATE517897T1 (de) 2011-08-15

Family

ID=36572091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06708816T ATE517897T1 (de) 2005-03-25 2006-03-27 Heterobicyclische inhibitoren von hvc

Country Status (12)

Country Link
US (1) US8030318B2 (de)
EP (1) EP1869037B1 (de)
JP (1) JP2008534479A (de)
KR (1) KR20070122194A (de)
AT (1) ATE517897T1 (de)
AU (1) AU2006226322B2 (de)
BR (1) BRPI0609650A2 (de)
CA (1) CA2602294C (de)
DK (1) DK1869037T3 (de)
MX (1) MX2007011850A (de)
RU (1) RU2405783C2 (de)
WO (1) WO2006100310A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035061A1 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
BRPI0609650A2 (pt) 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
AR054122A1 (es) 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
CN101443334A (zh) * 2005-12-21 2009-05-27 艾博特公司 抗病毒化合物
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
EP1979348B1 (de) * 2005-12-21 2012-01-18 Abbott Laboratories Antivirale verbindungen
CA2665438C (en) 2006-10-04 2014-12-02 Tibotec Pharmaceuticals Ltd. Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2291376A2 (de) * 2008-07-03 2011-03-09 Merck Patent GmbH Naphthyridininone als aurorakinasehemmer
ES2467108T3 (es) * 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
SMT201700026T1 (it) 2009-09-03 2017-03-08 Bristol Myers Squibb Co Chinazoline come inibitori dei canali degli ioni potassio
KR20120118008A (ko) * 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
ES2969977T3 (es) 2011-08-23 2024-05-23 Libertas Bio Inc Compuestos de pirimido-piridazinona y uso de los mismos
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HRP20201384T1 (hr) 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10376498B2 (en) 2014-10-29 2019-08-13 King Abdullah University Of Science And Technology 3-alkyl pyridinium compound from red sea sponge with potent antiviral activity
EP4585268A3 (de) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Feste formen von isochinolinonderivaten, herstellungsverfahren, zusammensetzungen damit und verfahren zur verwendung davon
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20190140011A (ko) 2017-04-28 2019-12-18 아사나 바이오사이언시스 엘엘씨 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789496A (de) * 1971-10-05 1973-03-29 S M B Anciens Ets J Muelberger
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
EP1317450B1 (de) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als protein-kinasehemmer
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
GB0127433D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
GB0127430D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
EP1485100B1 (de) 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azolylaminoazine als proteinkinasehemmer
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
WO2003078423A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions useful as inhibitors of protein kinases
DE60327999D1 (de) 2002-03-15 2009-07-30 Vertex Pharma Azolylaminoazine als inhibitoren von proteinkinasen
EP1511738A4 (de) * 2002-05-17 2007-05-09 Scios Inc Behandlung von fibroproliferativen erkrankungen unter einsatz von tgf-beta-inhibitoren
US7491367B2 (en) 2002-06-04 2009-02-17 Applera Corporation System and method for providing a standardized state interface for instrumentation
AU2003260072A1 (en) 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Antagonists of chemokine receptors
JP2006503043A (ja) 2002-09-10 2006-01-26 サイオス インク． ＴＧＦβ阻害剤
US20040138188A1 (en) * 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
WO2004048930A2 (en) 2002-11-22 2004-06-10 Scios, Inc. METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ß-ADRENERGIC PATHWAY
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
JP2006521398A (ja) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
WO2006035061A1 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
US20070066632A1 (en) 2005-03-25 2007-03-22 Scios, Inc. Fused bicyclic inhibitors of TGFbeta
BRPI0609650A2 (pt) 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
AR056347A1 (es) * 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
AR054122A1 (es) * 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas

Also Published As

Publication number Publication date
MX2007011850A (es) 2007-10-03
US20080182863A1 (en) 2008-07-31
KR20070122194A (ko) 2007-12-28
CA2602294C (en) 2015-02-24
BRPI0609650A2 (pt) 2010-04-20
WO2006100310A1 (en) 2006-09-28
DK1869037T3 (da) 2011-10-24
JP2008534479A (ja) 2008-08-28
EP1869037B1 (de) 2011-07-27
EP1869037A1 (de) 2007-12-26
AU2006226322B2 (en) 2012-03-29
AU2006226322A1 (en) 2006-09-28
CA2602294A1 (en) 2006-09-28
US8030318B2 (en) 2011-10-04
RU2007139453A (ru) 2009-04-27
RU2405783C2 (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
ATE517897T1 (de) Heterobicyclische inhibitoren von hvc
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
BRPI0512235A (pt) polipeptìdeos ligadores de antìgenos e seus usos
MX2020001497A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
DE60335717D1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
TW200636046A (en) Novel materials for organic electroluminescent devices
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
AP2139A (en) 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
TW200704751A (en) Novel materials for organic electroluminescent devices
EA200970738A1 (ru) Ингибиторы активности akt
ATE518010T1 (de) Aktive oberflächengekoppelte polymerasen
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EA201171081A1 (ru) Производные индола в качестве антагонистов рецептора crth2
EA200701802A1 (ru) Имидазо(1,2-а)пиридиновые соединения в качестве ингибиторов vegf-r2
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
ATE417051T1 (de) Polymorphe von clopidogrel-hydrogensulfat
CL2011003022A1 (es) Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer.
DE602004017486D1 (de) Substituierte heteroarylbenzofuransäuren
EA200700717A1 (ru) Сульфонамиды
ATE514765T1 (de) Azeotropartige zusammensetzungen mit 1,1,1,2,3,3- hexafluor-3-methoxypropan und 1-brompropan
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties